Podcasts about Biotechnology Innovation Organization

On this week's episode, Eric Schmidt, Sam Fazeli and Yaron Werber are joined by Biotechnology Innovation Organization's (BIO) John Crowley where they discuss biotech policy shifts, regulatory updates, obesity clinical trials and deal flow. The conversation begins with a focus on the obesity landscape including Novo Nordisk's CagriSema data, Roche's partnership with Zealand Pharma and Viking Therapeutics manufacturing agreements, signaling continued investment in the field. John Crowley then leads a conversation on policy and regulatory developments, sharing optimism about a more favorable U.S. policy environment for biotech. He highlights key priorities such as FDA modernization, PBM reforms and domestic manufacturing incentives. Crowley also notes bipartisan recognition of biotech as a strategic asset, though concerns persist around anti-science rhetoric, vaccine skepticism and regulatory challenges. Despite ongoing uncertainty, he sees more opportunities than threats for the industry. On the deal-making front, small-cap oncology acquisitions continue, with Sun Pharma acquiring Checkpoint Therapeutics and BMS consolidating its stake in 2seventy Bio. The discussion also covers biotech pipeline updates, including BioNTech's disappointing revenue guidance and Legend Bio's expansion of its CAR-T therapy manufacturing capacity. The episode concludes with insights into the broader biotech market, highlighting the impact of regulatory shifts, M&A activity and clinical trial data. While challenges remain, companies prioritizing innovation and execution continue to be well-positioned for long-term success. This episode aired on March 14, 2025.

In this episode of Moving Forward, Giving Back, Life Science Cares' CEO Sarah MacDonald sits down for a wide ranging and insightful conversation with John Crowley the President and CEO of the Biotechnology Innovation Organization. Known broadly as BIO, it is the world's largest biotechnology advocacy organization, representing biotechnology companies, academic and research institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.John and Sarah touch on and examine a number of topics including the urgent need to increase access to essential care, the rapid evolution of the industry over the last 50 years, the increased importance of storytelling for the industry in the modern communications era, as well as the promising future of biotech in the United States and beyond.We promise that you'll enjoy this exceptional and enlightening episode with our esteemed guest and host.Please go to lifesciencecares.org to learn more about the impact that Life Science Cares has had on the many communities that it serves throughout the United States. 

India could be the next big market for Wisconsin ginseng.  Kirk Baumann from Baumann Ginseng in Wausau just returned from a USDA trade mission to India.  He says there's some similarities between India and China - Wisconsin's number one market.  India also views ginseng as medicinal, but also incorporates it into teas and beverages.  Baumann says it'll take time, but he thinks there's opportunity there.  He explains the dynamics to Pam Jahnke. Emily Skor, CEO of Growth Energy, explains the ongoing battle in Washington, D.C. over reformulated fuel standards and consumer access. Pam Jahnke catches up with Ashley Huhn from the Steffes Group.  The number of auctions this month is slowing down with farmers in the field, but there's still plenty of interest. Stephanie Hoff focuses on the perception and realities of biotechnology in agriculture.  She's joined by Lynn Finnerty, senior director of public affairs at BIO. This group represents about 1,000 members in both the public and private sectors. Beth Ellikidis leads the agriculture and environment section at the Biotechnology Innovation Organization. BIO represents 1,000 companies, states, and colleges in biotechnology ranging from pharmaceuticals to agriculture. See omnystudio.com/listener for privacy information.

Tastier salad greens and heat-resistant cattle. These are products of genetic engineering that can help our food system be more efficient and sustainable, says Beth Ellikidis, vice president of agriculture and environment with the Biotechnology Innovation Organization. BIO represents about 1,000 stakeholders in genetic engineering, including companies, states, and colleges that dabble in everything from pharmaceuticals to seeds. She says the exact science of GE can bring a lot of value to the food sector. Lynn Finnerty, senior director of public affairs, says the benefits aren't always embraced by U.S. trade partners. Mexico, for example, is turning away from biotech corn. The EU has also been hesitant. However, Finnerty sees optimism ahead.See omnystudio.com/listener for privacy information.

This Day in Legal History: First Union FormedOn May 1, 1794, a pivotal development in labor rights history occurred in Philadelphia with the formation of the Federal Society of Journeymen Cordwainers. This organization, consisting of skilled shoemakers, marks the establishment of the first trade union in the United States. The union was created as a response to the increasingly difficult economic conditions that tradesmen faced, including low wages and long working hours.The Cordwainers, recognizing the strength in numbers, aimed to leverage their collective bargaining power to negotiate better wages and working conditions. This was a significant step forward in the labor movement, as it introduced the concept of organized labor in America. The formation of this union was not just about improving pay; it was also about dignifying the labor force and providing workers a platform to voice their concerns.Philadelphia, being a hub of commerce and trade in the late 18th century, provided the perfect setting for such an organization. The city's workshops and bustling markets meant that there was a significant demand for skilled labor, which the Cordwainers could supply. However, with industrialization beginning to take root, these skilled workers found themselves under threat from cheaper, mass-produced goods.The Federal Society of Journeymen Cordwainers set a precedent that would be followed by other trades across the country. Their actions led to the establishment of similar societies and unions, which eventually contributed to the broader national labor movement. The Cordwainers themselves faced legal challenges, particularly in 1806, when they were involved in a landmark legal case concerning the rights of workers to organize, known as Commonwealth v. Pullis. In this case, the court ruled against the union, marking one of the first legal battles over the legitimacy of trade union activities in the United States.Despite the legal setbacks, the resilience and pioneering spirit of the Federal Society of Journeymen Cordwainers inspired subsequent generations of workers to fight for their rights. Their legacy is a testament to the enduring struggle for fair labor practices and workers' rights. This day in legal history not only marks the formation of America's first trade union but also celebrates the long journey towards justice and equity in the workplace.The US Patent and Trademark Office (PTO) recently proposed a rule that would require pharmaceutical companies to submit unredacted settlement agreements involving patent challenges to a new repository. This rule is aimed to assist the Federal Trade Commission (FTC) and the Department of Justice (DOJ) in detecting antitrust violations. The proposal arose from concerns that these settlements, often reached in administrative tribunals like the Patent Trial and Appeal Board (PTAB), could be used to delay cheaper biosimilar drugs from entering the market.Evan Diamond, special counsel, noted that the PTO has not clearly defined "good cause" for accessing these agreements, which might increase third-party access and create confidentiality concerns. The fear is that the database could enable federal agencies to easily assess the frequency of potentially anticompetitive pay-for-delay settlements—a practice scrutinized under the Supreme Court's 2013 decision in FTC v. Actavis, which ruled such deals could be illegal.The proposal aligns with an executive order from President Joe Biden encouraging interagency cooperation to prevent practices that unjustifiably delay generic and biosimilar competition. This move has heightened the pharmaceutical industry's fears of increased antitrust enforcement, particularly as the FTC has been actively challenging questionable patent listings that could hinder the approval of generic drugs.Agencies like the FTC and DOJ already have certain reporting requirements under the Medicare Modernization Act for pharmaceutical companies, but the PTO's rule could capture additional agreements that do not meet existing criteria. This has sparked debate over the necessity and potential overlap of the new rule.The pharmaceutical industry, represented by major lobbyist groups like Pharmaceutical Research and Manufacturers of America and the Biotechnology Innovation Organization, has expressed strong opposition, citing concerns over the scope of PTO's authority and the ambiguity around the "good cause" criterion.This development highlights a broader regulatory push against anti-competitive practices not only in pharmaceuticals but also in other sectors like technology, where companies like Apple and Google are frequently involved in patent litigation.In summary, the PTO's proposed rule could significantly impact how pharmaceutical settlements are handled, potentially exposing companies to greater antitrust scrutiny. This measure reflects a governmental shift towards stricter oversight of patent practices to foster competition and reduce drug prices.Drug Makers Exposed to Antitrust Probes if Patent Cache AdoptedThis term, Jones Day had the highest number of attorneys—five in total—arguing cases at the U.S. Supreme Court, more than any other firm. Among them, John Gore and C. Kevin Marshall presented for the first time at the high court. Other experienced attorneys like former U.S. Solicitor General Noel Francisco, and partners Hashim Mooppan and Traci Lovitt also argued cases, contributing to the firm's visibility.In comparison, other leading law firms such as Gibson Dunn, Hogan Lovells, and Williams & Connolly had slightly fewer representatives. Gibson Dunn introduced three new attorneys to the Supreme Court lectern, including Theane Evangelis, D. Nick Harper, and Eugene Scalia, who is a son of the late Justice Antonin Scalia. Hogan Lovells' Jessica Ellsworth argued for the first time, including in a significant case regarding the abortion drug mifepristone. Williams & Connolly had Lisa Blatt argue all four of their cases, marking her 50th Supreme Court appearance.Overall, the season saw a mix of seasoned veterans and newcomers. Of the total 152 arguments made, over half were by attorneys who had appeared at least five times before, while a quarter were by first-time arguers. This highlights both the depth of experience and the ongoing introduction of new talent in the legal field's highest echelons.Jones Day Leads in Supreme Court Arguments With New FacesJohnson & Johnson (J&J) is currently seeking approval for an $11 billion settlement to resolve ongoing litigation concerning its talc-based baby powder, which has been alleged to cause ovarian cancer. This amount is a significant increase from a previous offer of $8.9 billion. J&J's strategy involves a third attempt at a bankruptcy filing, specifically a pre-packaged bankruptcy, which allows for faster processing if they secure enough creditor support—in this case, needing the approval of 75% of the talc plaintiffs.The company proposes to pay $6.48 billion over 25 years to settle ovarian cancer claims, but it has not specified how funds will be divided between existing and future claims. Additionally, J&J has nearly settled all claims regarding mesothelioma believed to be caused by asbestos in the powder. This settlement approach follows multiple failed attempts to use Chapter 11 to manage these lawsuits, which now number almost 60,000.These lawsuits have been a significant factor depressing J&J's stock price, according to analysts. Despite the legal challenges, J&J maintains that its talc products do not cause cancer and asserts that it has marketed its baby powder responsibly for over a century. A recent verdict, however, led to a $45 million payout to a family, implicating J&J and its spinoff Kenvue in the ongoing litigation.The company's persistence in seeking a bankruptcy-based settlement reflects its strategic approach to managing a complex legal challenge that impacts thousands of plaintiffs and could potentially set a precedent in how large corporations handle mass tort liabilities through bankruptcy court.J&J Seeks Backing for $11 Billion Baby Powder Cancer SettlementIn President Joe Biden's Fiscal Year 2025 Budget Proposal, a notable change is the suggestion to tax unrealized gains—value increases in assets not yet converted into cash through a sale. This marks a significant shift from traditional tax frameworks, which typically avoid taxing unrealized gains due to their complexity, potential liquidity issues, and difficulties in implementation.The rationale behind this proposal is to ensure tax fairness by capturing increases in wealth that currently escape taxation. For example, if a billionaire's stock appreciates significantly without being sold, they realize no taxable gain. However, if they borrow against these increased values, they effectively use this appreciation as a means to generate wealth without incurring tax liabilities. This situation presents a loophole where wealth can grow and be leveraged without contributing to the tax base.The FY2025 budget aims to address these disparities by proposing a tax on unrealized gains for very high-net-worth individuals and entities that have not been subject to a tax event in the last 90 years. This approach seeks to broaden the tax base without raising rates, aiming to increase tax revenue from the wealthy without additional burdens on middle and lower-income individuals.This policy shift acknowledges the need to adapt tax strategies to a changing economic environment where traditional taxation methods no longer capture all forms of wealth accumulation. The proposal suggests that a more equitable tax system requires taxing wealth as it grows, even if it is not realized through a sale. By proposing to tax unrealized gains, the administration intends to correct imbalances allowing substantial wealth to accumulate tax-free, signaling a significant potential change in how wealth is taxed in the U.S.Unrealized Gain Tax—A Coming Sea Change in FY2025 Budget Proposal? Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe

Welcome to Season 2 of ‘That's Understandable'! In this episode, Brendan welcomes guests Dr. Cartier Esham of the Biotechnology Innovation Organization, Pam Traxel of the American Cancer Society Cancer Action Network and Diane, a cancer survivor in a conversation around drug pricing and medical innovation.  The Biotechnology Innovation Organization (BIO) is a proactive voice of science and for science that is driving a “bio revolution” to cure patients, protect our climate and nourish humanity.  The American Cancer Society Cancer Action Network (ACS CAN) is a nonprofit, nonpartisan advocacy affiliate of the American Cancer Society. ACS CAN advocates for evidence-based public policies to reduce the cancer burden for everyone. It engages volunteers throughout the US to advocate at every level of government. 

This week's guest on Open Mic is Beth Ellikidis, Vice President, Agriculture and Environment for the Biotechnology Innovation Organization. The Biden administration recently announced its Bioeconomy Board, creating new products and services to boost the U.S. economy and workforce and enhance our quality of life and the environment. Ellikidis says BIO's goal is simply to advocate for the possible. She sees products that will improve agriculture productivity while at the same time lessen the industry's environmental footprint. Ellikidis says the nation's regulatory structure is strained to keep up with scientific advancements provided by fast-moving private industry research.

Biotech companies are addressing climate change through innovation—from carbon neutral facilities to agricultural innovations to reduce greenhouse gas emissions. BIO was on the ground at the COP28 UN Climate Change Conference in Dubai to deliver the message that biotech is climate tech.Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

Our teacher today is John Crowley. It is difficult to appropriately describe John and the Crowley family's story without drawing comparisons to superheroes. Harrison Ford gave it a shot, and the result is Extraordinary Measures, a blockbuster movie he starred in, alongside Brendan Fraser and Kerry Russell. The movie is based on Gita Anand's book The Cure, which tells the story of John and his wife's journey to save two of their children from a then-untreatable disease called Pompe. Thanks to John, that's no longer the case, and now more than 20 years later, both of his children and many others with Pompe are not only still living, but thriving. Since that time, John's gone on to build several successful biotech companies, including Amicus Therapeutics and Novozyme. And just a few days before the release of this class, it was announced that John is now the new CEO of Biotechnology Innovation Organization, or BIO, which is the leading biotech advocacy, education, and policy organization in the world. There's nobody more purpose-built to give us a history lesson on the biotech industry. Please enjoy this class with the incredible John Crowley. For the full show notes, transcript, and links to mentioned content, check out the episode page here. ----- This episode is brought to you by Summus. Summus is a revolutionary health benefits solution, driving superior employee engagement while dramatically lowering your company's enterprise-level healthcare spend. They're completely transforming the world of health benefits by providing employers and their employees in any location, fast access to over 5,100 of the top medical specialists from America's very best medical centers for support across all health questions. If you're looking for a benefit that drives your employee engagement, truly takes care of your people in their most scary and vulnerable times, all while improving your healthcare ROI, visit GoSummus.info/AOI. This episode is brought to you by Hunt Club. Hunt Club unlocks relationships and helps companies grow. Whether it's recruiting your next hire, landing your next big partner, or financing your business, a trusted introduction always works more effectively. Hunt Club's tech-enabled search model leverages the largest community of its kind to refer amazing talent on your behalf. Additionally, its software program, Atlas, helps organize the entire network of a company or fund and assists in streamlining the right introductions. If you're looking for the ideal solution for all of your talent needs, visit HuntClub.com/AOI. ----- Art of Investing is a property of Pine Grove Studios in collaboration with Colossus, LLC. For more episodes of Art of Investing, visit joincolossus.com/episodes.  Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Show Notes (00:00:00) Welcome to the Art of Investing (00:05:09) First Question - The Young John Crowley  (00:09:53) An Educational Odyssey - Naval Academy to Harvard (00:12:40) Embracing Challenges and Pivots in Life (00:16:00) The Crowley's Battle with Pompe Disease (00:23:59) The Biotech Industry's Evolution at the Turn of the Century (00:26:02) The Promise and Challenges of Gene Therapy (00:30:54) The Journey of Starting a Biotech Company: From Novozyme to Amicus (00:32:55) The Challenges and Triumphs of Drug Discovery and Commercialization (00:38:12) Advice for Aspiring Biotech Investors (00:42:26) The Ambitious Vision of Amicus (00:48:10) Acquiring New Technologies and Overcoming Financial Hurdles (00:54:19) John's Personal Triumphs Amidst Professional Challenges (01:02:08) Megan Crowley's Journey and Family Pride (01:14:07) The Current State and Future of Biotechnology (01:21:28) The Impact of M&A in Biotech and Pharma (01:29:11) Leadership Lessons from the Frontlines of Biotech (01:34:32) Balancing Life, Duty, and Passion (01:36:09) Reflecting on Legacy and Purpose

Sarah Gallo is Vice President of Product Policy at the Consumer Brands Association (CBA). In her role, Sarah holistically oversees Consumer Brands' policy leadership on smart regulation issues, from advocacy through education to marketplace solutions. Prior to joining CBA, she served as Vice President of Agriculture and Environment for the Biotechnology Innovation Organization, where she led the organization's strategy across agriculture, food systems, energy, and bio-based manufacturing. Earlier in Sarah's career, she held roles at CHS Inc. and the National Corn Growers Association and served as Agriculture Counsel with the U.S. House of Representatives Committee on Small Business. She graduated from Boston University with a B.A. in Marine Biology. In this episode of Food Safety Matters, we speak with Sarah [24:28] about: CBA's key recommendations for FDA during its restructuring, and how those suggestions are  informed by looking at FDA modernization through the lens of the consumer Specific changes that CBA believes could help FDA transition from one-size-fits-all inspections to a tailored, risk-based model for inspections CBA's partnership with Stop Foodborne Illness and FDA, which aims to improve recall communication through the use of modernized channels and digital technologies CBA's call to FDA to standardize labeling and “last mile” communication in e-commerce food sales, and the Association's work to support FDA's development of such standards How digital tools that are already being leveraged by industry—like SmartLabel technology—can be better used to modernize labeling, and why nutrition and consumer transparency must go hand-in-hand when thinking about front-of-pack labeling Why FDA action regarding regulation for chemicals of concern in food packaging—such as PFAS and BPA—is urgent to avoid a wave of contradictory, state-by-state legislation The benefits of public-private collaboration in the creation of FDA guidances for industry, as well as guidances that CBA believes are important for FDA to develop. Dr. José Emilio Esteban was sworn in as Under Secretary for Food Safety on January 4, 2023. In this role, Dr. Esteban leads the Office of Food Safety at the U.S. Department of Agriculture (USDA), overseeing the Food Safety and Inspection Service (FSIS), which has regulatory oversight for ensuring that meat, poultry, and egg products are safe, wholesome, and properly labeled. Prior to his confirmation, he was chief scientist at FSIS. In this capacity, Dr. Esteban served as the primary scientific advisor on matters of public health and food safety that affect the mission of the agency, with primary responsibility for scientific initiatives within the FSIS Office of Public Health Science (OPHS). His prior positions at FSIS include Science Advisor for Laboratory Services and Executive Associate for Laboratory Services. Prior to joining FSIS, Dr. Esteban worked in several positions at CDC. He holds a doctorate in veterinary medicine (D.V.M.), an M.B.A., and a master's degree in Preventive Veterinary Medicine, as well as a Ph.D. in Epidemiology. In this episode of Food Safety Matters, we speak with Dr. Emilio Esteban [3:08] about: Food safety, food security, and the global food system post-pandemic USDA's Proposed Regulatory Framework to Reduce Salmonella Illnesses Attributable to Poultry The steps that need to be taken to recruit and retain more veterinary doctors to address the ongoing shortage of D.V.M.s and ensure a safe food supply Recent developments around cell-cultured/lab-grown meat Ongoing work with the Agricultural Research Service on "raised without antibiotics" claims Dr. Esteban's three key principles of leadership  We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com

Entrepreneurs and investors often grapple with the complexities of the biotech industry. The high risk associated with drug development, coupled with the intricate regulatory environment, can make biotech investments seem daunting. Moreover, the need for substantial capital and the long timeline for potential returns can further complicate the investment decision.This clip provides a comprehensive overview of the biotech investment landscape, offering valuable insights from industry experts. By watching this clip, you will understand the challenges and opportunities in biotech investments, learn about the importance of patient capital, and discover strategies to mitigate risks. This knowledge can empower you to make informed investment decisions, potentially leading to high returns and contributing to advancements in healthcare and medicine.

Navigating the biotech industry's rapid advancements and complex regulations can be daunting. High-stakes investments and the pressure to innovate further add to the challenge.Rich Masters, the CMO of BIO (Biotechnology Innovation Organization), is a seasoned expert in this field. His role in organizing the BIO International Convention and his extensive industry experience equips him with unique insights to tackle these challenges.In this fantastic podcast episode, we delve into:

What do GMOs, food and Mexico have in common? Most corn grown in the United States has been improved using biotechnology and the Mexican government has proposed banning some of our corn exports to the country, potentially impacting demand and food security. Sorting the issue out is Lynne Finnerty, agriculture and environment communications director, Biotechnology Innovation Organization, and David Salmonsen, senior director, government affairs, American Farm Bureau Federation.

In healthcare, they say the only constant is change. Medical practices and treatments are always evolving, and today's guest is on the cutting edge of an exciting development. Today we're sitting down with Dr. Eddie Sullivan, co-founder, President and CEO at SAB Biotherapeutics. Eddie served in biopharma leadership positions for more than 25 years, and prior to joining SAB, he was CEO of Hema Tech, where he led initiatives to develop infectious disease, cancer, and autoimmune immunotherapies. A recognized thought leader in antibodies in transgenic animals, Eddie serves on the board of directors for the Biotechnology Innovation Organization, he's earned two PhDs in health science administration and reproductive physiology, and he holds an MS in reproductive physiology and molecular biology, and a BS in Animal health sciences.On the show, we talk to Eddie about SAB's polyclonal antibody research, perceptions about this research in the biotech world, and the future of fighting diseases. Highlights: Eddie's path to the Biotherapeutics field (3:04) Founding SAB and the immunotherapy industry (3:41) How SAB uses cows for research (4:59) SAB's take on the COVID vaccine (8:43) Perceptions of monoclonals vs. polyclonals (13:27) Slow growth in polyclonal research (16:57) SAB's work on Type 1 Diabetes and other disease treatment (20:13) What Eddie is excited about in the future for the field (26:19) The biggest challenge in biotech (27:10) Links:ICR TwitterICR LinkedInICR WebsiteDr. Eddie Sullivan on LinkedInSAB Biotherapeutics on LinkedinSAB Biotherapeutics WebsiteFeedback:If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, marion@lowerstreet.co.

Not that long ago psychedelics were considered dangerous, and only enjoyed recreationally by a fringe element of society. Today, researchers are looking at drugs like psilocybin to develop treatments for depression, PTSD, addiction, and anxiety. This episode features guests steeped in the world of psychedelics who are finding new ways to treat mental health. Guests:Dr. Frank Wiegand, Chief Medical Officer, Beckley PsytechKurt Rasmussen, Ph.D., Chief Scientific Officer, Delix TherapeuticsClara Burtenshaw, Co-founder and Partner, Neo Kuma Ventures

Not that long ago psychedelics were considered dangerous, and only enjoyed recreationally by a fringe element of society. Today, researchers are looking at drugs like psilocybin to develop treatments for depression, PTSD, addiction, and anxiety. This episode features guests steeped in the world of psychedelics who are finding new ways to treat mental health. Guests:Dr. Frank Wiegand, Chief Medical Officer, Beckley PsytechKurt Rasmussen, Ph.D., Chief Scientific Officer, Delix TherapeuticsClara Burtenshaw, Co-founder and Partner, Neo Kuma Ventures

In this episode of Black Power Moves, part of the Ebony Covering Black America Podcast Network, we're speaking to Donna Cryer, Founder, President & Chief Executive Officer of Global Liver Institute. https://www.globalliver.org/ GLI is the premier patient-driven liver health nonprofit operating across the globe. Moved by her own experience as a liver transplant recipient, Donna has become a powerful force in liver health, health policy, and patient advocacy. At GLI, she has raised more than $10 million for liver health initiatives. She has been featured by and worked with Congress and the White House to advance equitable healthcare in both organ procurement and information technology. Donna is a frequent speaker on patient centricity in research and healthcare delivery and patient engagement in healthcare transformation at meetings of Biotechnology Innovation Organization, Pharmaceutical Research and Manufacturers of America, America's Health Insurance Plans, National Quality Forum, National Comprehensive Cancer Network®, and the National Academy of Medicine.  She frequents the stage of national platforms, including The Washington Post Live, SXSW, and The Atlantic's People v. Cancer. Learn more about your ad choices. Visit megaphone.fm/adchoices

Changing the Dialogue Around Science From research related to COVID-19 to more sustainable foods, scientists are developing amazing new ways to build and support a healthier planet. But if the vast majority of the world's population cannot access and benefit from these incredible innovations, their value is limited. Dr. Michelle McMurry-Heath, the head of the Biotechnology Innovation Organization, tells us that the distribution of scientific progress is the social justice issue of our age. She discusses how biotechnology can help solve food safety, sustainability and food access issues – and the importance of delivering these advancements into people's lives no matter where or how they live. Tune in to this episode with guest Dr. Michelle McMurry-Heath to learn about: the intersection of science and social justice the important role that science, biotechnology and innovation play in human health, environmental stewardship and sustainable agriculture broadening access to scientific progress so more people from diverse backgrounds can benefit from cutting-edge innovation social justice advocacy McMurry-Heath's new book “Just Science” coming out soon helpful resources and takeaways for the general public and healthcare professionals to learn more and get involved Full shownotes and resources at: https://soundbitesrd.com/211    

Richard Haass and Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Institute, discuss the future of biotechnology and its potential impact on food production, climate change, energy production, and medicine.   Episode Guest:  Michelle McMurry-Heath (President and CEO, Biotechnology Innovation Organization).   This episode is based on a live event that took place on September 29, 2021.   For an episode transcript and show notes, visit us at: https://www.cfr.org/podcasts/can-biotech-be-harnessed.

My returning guest today is Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics and the immediate past Chairman of the global Biotechnology Innovation Organization. He has been voted one of the 25 most influential people in the biopharmaceutical industry. Prior to Ovid, Dr. Levin served as President and CEO of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) the world's largest generics drug company.

Fulfilling a campaign promise to “free the vaccine”, US President Joe Biden said he would support lifting patent protection on coronavirus vaccines, to make it easier for vaccines to get to people around the world who need them quickly. But several Western governments and most drug manufacturers opposed his stance, arguing that Big Pharma would have little incentive to produce a vaccine in record time the next time a new global health emergency arises. Host Steve Clemons speaks to Dr Michelle McMurry-Heath, president of the trade group Biotechnology Innovation Organization; and Ed Luce, a US columnist for the Financial Times. - Subscribe to our channel: http://aje.io/AJSubscribe - Follow us on Twitter: https://twitter.com/AJEnglish - Find us on Facebook: https://www.facebook.com/aljazeera - Check our website: https://www.aljazeera.com/

In this episode of On Record PR, Executive Vice President Sarah Larson goes on record with James Greenwood, senior policy advisor at DLA Piper, retired CEO of the Biotechnology Innovation Organization, and former congressman representing Bucks County, Pennsylvania. Learn more Jim Greenwood started his career as a social worker focusing on abused and neglected children in 1980. At the age of 29, he was elected to the Pennsylvania House of Representatives and six years later to the state Senate. In 1992, he was elected to Congress and would go on to represent Pennsylvania's eighth congressional district for six terms from 1993 to 2005. In 2005, Jim voluntarily left Congress to serve as the president and CEO of the Biotechnology Innovation Organization. After 15 years at the helm of BIO, he recently joined DLA Piper where he now chairs the Life Sciences, Health, Policy and Regulatory Group.

Hello and welcome to the ZimmCast. Since it is Ag Week I want to say thank you to farmers and everyone in the food and agribusiness industries for helping feed the world. Ag Week emphasizes the importance of agriculture and in this program I’m sharing a conversation about a new impact study of the food industry to the U.S. economy. It’s titled, “2021 Food and Agriculture Industries Economic Impact Study.” To learn more about it I visited with Connor McKoy, Communications Director for the Biotechnology Innovation Organization. The study is impressive and there is a whole website dedicated to it and making the information simple to navigate. After that discussion I move on to how farms and rural households can enhance and extend their wifi coverage with new products from Ayrstone Productivity. Bill Moffitt, President, talks about their newest Ayrmesh products. So, that’s the ZimmCast for this week. I hope you enjoyed it and thank you for listening. If you like what you hear in the ZimmCast please subscribe in any of the major platforms. And you can also search for the ZimmComm Golden Mic Podcast too, which includes all the audio we produce. If you would like to advertise in the ZimmCast or become an on-going sponsor please let me know and we’ll work out a plan just for you.

William J. Newell has served as our Chief Executive Officer and a member of our Board of Directors since January 2009. Previously, he served as the President of Aerovance, Inc., a biotechnology company focused on respiratory diseases, from 2006 to 2007. Mr. Newell has also served as the Chief Business Officer and Senior Vice President at QLT Inc., in several senior management positions at Axys Pharmaceuticals, Inc., and has experience as a corporate lawyer. He currently serves on the boards of directors of a private biotechnology company, the Biotechnology Innovation Organization’s Health Section and Emerging Company Section and the California Life Sciences Association, where he also serves as a member of the executive committee. Mr. Newell received an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan Law School. We believe that Mr. Newell is qualified to serve on our Board of Directors because of his experience with various biotechnology companies, including working with and serving in various executive positions in life sciences companies.

Trailing in the polls this fall, President Trump dusted off the 2016 campaign playbook and went after the drug companies again. But channeling anger at the companies the whole world is depending on to end the pandemic was always dicey politics. Post-election, the Trump administration hastily issued a final rule setting Medicare Part B reimbursement rates at the lowest levels charged by counties in the developed world, which ration medicines and leave the sick untreated. BIO took the administration to court, and we won when a federal court issued an injunction blocking the rule.

Dr. Michelle McMurry-Heath is President and CEO of Biotechnology Innovation Organization, also known as BIO. In this episode, she sits down with Steve to talk about her group, the COVID-19 crisis and vaccine rollout, her commitment to diversity in her industry, and her hopes for the future of biotechnology and medicine.

Dr. Jeremy Levin is the chairman of the Biotechnology Innovation Organization. He is also the CEO of OVID Therapeutics. Formerly, he was a member of the executive committee at Bristol-Myers Squibb and chairman and CEO of TEVA Pharmaceuticals—where he was personally recruited by the President of Israel. He is the scientist who introduced immuno-oncology to the world 10 years ago and has been called one of the most influential figures in the biopharmaceutical industry. On top of that, Dr. Levin has a fascinating life story, having been forced to flee South Africa during apartheid, and later working to develop vaccines in the heart of the Israeli–Palestinian conflict. Dr. Levin earned his B.A. in zoology, M.A. in cell biology and Ph.D. in chromatin structure, all from the University of Oxford, and his medical degree from the University of Cambridge. –––– Support the podcast and join the Honest Offense community at https://honestoffense.locals.com

What do health tests and vaccines have to do with growing food? Both have benefited from science that has helped lead to COVID-19 tests and vaccines and potentially more climate-smart, nutritious foods and other products. Fan-Li Chou, vice president, scientific affairs and policy for the American Seed Trade Association, and Clint Nesbitt, senior director, science and regulatory affairs for the Biotechnology Innovation Organization, shed some light on the topic

What do health tests and vaccines have to do with growing food? Both have benefited from science that has helped lead to COVID-19 tests and vaccines and potentially more climate-smart, nutritious foods and other products. Fan-Li Chou, vice president, scientific affairs and policy for the American Seed Trade Association, and Clint Nesbitt, senior director, science and regulatory affairs for the Biotechnology Innovation Organization, shed some light on the topic

COVID-19 is now the third leading cause of death in the United States, FDA announces emergency authorization for convalescent plasma to treat COVID-19, and are neck gaiters useful as face coverings? Turns out yes, they are fine. With the end of mask-wearing not being anywhere in sight, entrepreneurs are finding innovative ways to make them at least more comfortable. By holding the fabric just a few millimeters away from the nose and mouth, the new HeartForm mask accessory facilitates breathing, keeps wet face mask material away from the face,  and makes it easier to talk. Paul Dobbins tells us more about what he and his partner Maggie Dobbins created.And everyone is hoping for a COVID 19 vaccine to come around as soon as possible. But how soon is...too soon? Russia says they have a vaccine and other places say they will have one by the end of the year. I talked to Dr. Jeremy Levin about the latest in COVID vaccines - he is a scientist and the Chairman of the global Biotechnology Innovation Organization.As always, feel free to reach out to us at any time with questions or ideas at Covid19@RadioMD.com.

COVID-19 is now the third leading cause of death in the United States, FDA announces emergency authorization for convalescent plasma to treat COVID-19, and are neck gaiters useful as face coverings? Turns out yes, they are fine. With the end of mask-wearing not being anywhere in sight, entrepreneurs are finding innovative ways to make them at least more comfortable. By holding the fabric just a few millimeters away from the nose and mouth, the new HeartForm mask accessory facilitates breathing, keeps wet face mask material away from the face,  and makes it easier to talk. Paul Dobbins tells us more about what he and his partner Maggie Dobbins created.And everyone is hoping for a COVID 19 vaccine to come around as soon as possible. But how soon is...too soon? Russia says they have a vaccine and other places say they will have one by the end of the year. I talked to Dr. Jeremy Levin about the latest in COVID vaccines - he is a scientist and the Chairman of the global Biotechnology Innovation Organization.As always, feel free to reach out to us at any time with questions or ideas at Covid19@RadioMD.com.

The number of confirmed coronavirus cases in the United States has surpassed two million, but medical professionals say there are some promising developments in treatments and vaccines. The speed and scale in which companies are operating at to combat the coronavirus is unprecedented, but the process of developing a vaccine remains very complicated. FOX's Trey Yingst speaks with Dr. Michelle McMurry-Heath, MD, PhD, President of the Biotechnology Innovation Organization, on how the United States has handled the virus outbreak.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The number of confirmed coronavirus cases in the United States has surpassed two million, but medical professionals say there are some promising developments in treatments and vaccines. The speed and scale in which companies are operating at to combat the coronavirus is unprecedented, but the process of developing a vaccine remains very complicated. FOX's Trey Yingst speaks with Dr. Michelle McMurry-Heath, MD, PhD, President of the Biotechnology Innovation Organization, on how the United States has handled the virus outbreak. 

Clare Thorp is currently the Senior Vice President, for Creme Global where she works with companies and government agencies to support their decision-making processes through the harnessing of big data and deployment of advanced computational tools. Since 2010, Clare has held executive leadership positions in trade associations and non-profits including CropLife America, the Biotechnology Innovation Organization and the International Life Sciences Institute of North America. Cronan McNamara is the founder and CEO of Crème Global, where he pursues his passion in applying data and predictive models to solve problems in order to help people to make better decisions. Prior to founding Creme Global in 2005, Cronan worked in financial risk analysis and derivative option price modeling with Merrill Lynch Capital Markets Bank. Cronan then moved to Trinity College Dublin where he adapted the same mathematical methods to the food safety sector while developing the science and technology that underpins Creme Global.   Homepage: https://www.cremeglobal.com/ Cronan's LinkedIn: https://www.linkedin.com/in/cronanmcnamara/ Clare's LinkedIn: https://www.linkedin.com/in/clare-thorp-ph-d-bbb52930/ Creme Global's Twitter: @cremeglobal  Cronan's Twitter: @cronanmcnamara Clare's Twitter: @ClareAgSciNerd     To learn more about Aigora, please visit www.aigora.com  

Jim Greenwood, President and CEO of the Biotechnology Innovation Organization, and the former long-term congressman from Pennsylvania’s 8th District, joined us as part of Intercontinental Exchange’s ongoing series on the latest information and perspectives on the coronavirus pandemic. Jim shared how the 1,000+ biotech companies, academic institutions, state biotech centers, and other organizations that BIO represents are producing the cures, vaccines, and other protocols required to reopen the nation.                                                      Inside the ICE House: https://www.theice.com/insights/conversations/inside-the-ice-house

A conversation with Jeremy Levin, chairman of the Biotechnology Innovation Organization and CEO of Ovid Therapeutics, about industry versus government responses to covid19, the split within biotech on how to address charges of high prices, and why the biopharma industry is so disliked. See acast.com/privacy for privacy and opt-out information.

Dana O'Brien, Executive VP of Food and Agriculture at the Biotechnology Innovation Organization, and Andy LaVigne, President and CEO of the American Seed Trade Association discuss the biotech industry from an environmental perspective.  Andy LaVigne, President and CEO of the American Seed Trade Association   Dana O'Brien, Executive VP of Food and Agriculture at the Biotechnology Innovation Organization   Biotech is important for feeding the world with nutrients, mitigating food waste, and developing crops that are more resilient for climate change. 

Story 1: Senator Chuck Grassley on boosting the ethanol market in 2020. Story 2: Biotechnology Innovation Organization and Low Carbon Fuels Coalition announce new joint initiative. Story 3: LanzaTech moving ahead on Sustainable Aviation Fuel scale up.

Shaughnessy and former Congressman Jim Greenwood, CEO of the Biotechnology Innovation Organization, discuss the partisan divide, serving in Congress during an impeachment inquiry, and what biotech and pharma have proposed to address prescription drug prices and help combat the opioid crisis. Follow Jim on Twitter: @JimGreenwoodFollow Shaughnessy on Twitter: @VoteShaughnessy

On this week’s Tech Nation, Moira speaks with the committed people who lead the biotech industry. Physician-entrepreneur Dr. Jeremy Levin chairs BIO, the Biotechnology Innovation Organization, and also works on the rare disease Angelman Syndrome at Ovid Therapeutics. Jim Greenwood, the CEO of BIO, asks “What’s the right thing to do?” about the price of drugs and everyday people. While BIO Vice Chair, Paul Hastings, is also the CEO of Nkarta Therapeutics. With Senior Vice President, Nadir Mahmood, they’re working with Natural Killer cells to fight cancer.

On this week’s Tech Nation, Moira speaks with the committed people who lead the biotech industry. Physician-entrepreneur Dr. Jeremy Levin chairs BIO, the Biotechnology Innovation Organization, and also works on the rare disease Angelman Syndrome at Ovid Therapeutics. Jim Greenwood, the CEO of BIO, asks “What’s the right thing to do?” about the price of drugs and everyday people. While BIO Vice Chair, Paul Hastings, is also the CEO of Nkarta Therapeutics. With Senior Vice President, Nadir Mahmood, they’re working with Natural Killer cells to fight cancer.

On this week’s Tech Nation, Moira speaks with the committed people who lead the biotech industry. Physician-entrepreneur Dr. Jeremy Levin chairs BIO, the Biotechnology Innovation Organization, and also works on the rare disease Angelman Syndrome at Ovid Therapeutics. Jim Greenwood, the CEO of BIO, asks “What’s the right thing to do?” about the price of drugs and everyday people. While BIO Vice Chair, Paul Hastings, is also the CEO of Nkarta Therapeutics. With Senior Vice President, Nadir Mahmood, they’re working with Natural Killer cells to fight cancer.

The BIO International Convention, the world’s premier life sciences event, will return to Philadelphia, PA, from June 3-6 and is expected to attract more than 16,000 attendees and 1,800 exhibitors from 67 countries. The theme of this year’s convention is “It Starts with One.” Jim Greenwood, President and CEO of the Biotechnology Innovation Organization talks about the challenges, obstacles and future of biotechnology.

The BIO International Convention, the world’s premier life sciences event, will return to Philadelphia, PA, from June 3-6 and is expected to attract more than 16,000 attendees and 1,800 exhibitors from 67 countries. The theme of this year’s convention is “It Starts with One.” Jim Greenwood, President and CEO of the Biotechnology Innovation Organization talks about the challenges, obstacles and future of biotechnology.

May 27, 2019 Memorial Day Intro to Summer Special! Small Business Outlook Remains Strong, CEO of the Biotechnology Innovation Organization, Preparing for Natural Disasters and Summer Education

Season 2 Episode 10: BIO 2019 Convention: Insights from BIO CEO Jim Greenwood | Growing Greater From June 3rd-6th, 2019, the largest global event for biotechnology is happening right here in Philadelphia. Greater Philadelphia region’s unparalleled talent pool in the life sciences, biopharmaceuticals, and healthcare space, is just one reason why this momentous event is taking place here in just a few short weeks! In this special episode, we talk all things BIO with Jim Greenwood, president and CEO of this special organization. “BIO” which is an acronym for Biotechnology Innovation Organization is based out of Washington DC and represents biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 countries worldwide. We gathered with a live studio audience at Thomas Jefferson University and Jefferson Health for our behind the scenes look at BIO and the upcoming 2019 BIO International Convention.

This week's guest on Open Mic is Andy LaVigne, President and CEO of the American Seed Trade Association. In this week's interview LaVigne discusses the two biggest issues facing his industry: trade and acceptance of new technology. LaVigne applauds the Trump administration for taking on longstanding obstacles to fair trade and a new information partnership with the Biotechnology Innovation Organization. Innovature is a new platform designed to encourage conversations around innovation in food and agriculture. LaVigne says the initial focus is on gene editing which he says can help preserve the planet, improve consumer health, and increase food production.

Read the complete transcription on The Sales Game Changers Podcast website. ERIC'S FINAL TIP TO EMERGING SALES LEADERS: "You're going to have times where you're really in a funk. Take a step back, think about some of the good wins that you've had for those days. Take a step back and say, "I've done this before, I've been in this situation before" from a mentality standpoint and say, "I'm going to really sell my way out of it.” That will work. Eric Misic is the VP of Business Development at Bear Analytics. Prior to starting Bear Analytics he held business development leadership role at the Biotechnology Innovation Organization and the Convention Management Group.

On this episode we're talking about biology. Not your high school biology, though; we're talking about biotechnology and biofuels with Paul Winters, Director of Communications, and Erick Lutt, Director of Industrial and Environmental Policy, for BIO, the Biotechnology Innovation Organization. Paul and Erick start off with the basics of how agricultural products such as corn are converted into biofuels such as ethanol. Then the discussion covers how biofuels are more climate friendly than fossil fuels; how renewable fuel standards have impacted the biofuels industry both domestically and abroad; how the current political dynamic looks for biofuel support; why BIO believes the federal government should continue to support development and production of biofuels; and closes with a prediction about biochemical production and use of biofuels in the aviation industry. Recorded April 27, 2017 Published May 8, 2017

This past year, Ron took over the role of Chair of BIO, the Biotechnology Innovation Organization. From that vantage point, he comments on the high drama in 2015 that has entertained - and sometimes threatened - the industry. He discusses inter partes review, the right and wrong conversations on drug pricing, and the choices that determine the pace of R&D within our ecosystem of brilliant science and entrepreneurship. He also projects some hot trends and throws down the gauntlet for biotech in NY. If you listen carefully, you can hear him pounding the table. This episode, Part 2 of the two-part interview, picks up where Part 1 left off, on the subject of social media's role in biotech.

Rachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens. See acast.com/privacy for privacy and opt-out information.